HUTCHMED will host a webcast to discuss the data presented at the ASCO Annual Meeting at 8:30 -9:00 am HKT on Tuesday, June 3, 2025 (8:30 - 9:00 pm EDT on June 2, 2025). The event will be held in ...

Nxera and Lilly entered the multi-target collaboration in 2022 to leverage Nxera’s GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and ...

In the Phase 1/1b trial, ficerafusp alfa in combination with pembrolizumab resulted in deep and durable anti-tumor activity with improved overall survival (OS) compared to historical benchmarks in ...

Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali ® (ribociclib) plus endocrine therapy (ET, a non-steroidal ...

Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV) and early-stage sensitivity for multiple cancers with elevated ...

“Patients whose tumors harbor ESR1 mutations can face a poor prognosis, often experiencing rapid disease progression on endocrine therapy,” said Johanna Bendell, M.D., Chief Oncology Development ...

Key results from the interim analysis of the Phase 3 ENLIGHTED study of Padeliporfin VTP: As of November 5, 2024, the data cut-off for the poster presentation at ASCO, 43 patients had begun treatment, ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...

A copy of the Early Warning Report filed by CEO will be available under the Company’s profile on SEDAR at www.sedarplus.ca or may be obtained from José Roldan, Interim CFO, at [email protected].

Less than half of patients diagnosed with TD residing in LTC settings received the standard of care treatment recommended by the American Psychiatric Association – a vesicular monoamine transporter 2 ...

NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (“ 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today ...